TGBA01AD

TGBA01AD
Clinical data
Routes of
administration
Oral
Pharmacokinetic data
Bioavailability 17%
Biological half-life 4 hours
Identifiers
Synonyms FKB01MD

TGBA01AD (also known as FKB01MD) is a serotonin reuptake inhibitor, 5-HT1A and 5-HT1D receptor agonist, and 5-HT2 receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder.[1] [2] It has been in phase II clinical trials since 2009, and as of January 2016, remains in this phase of development.[3]

See also

References



This article is issued from Wikipedia - version of the 10/26/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.